Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 124Lymphoma 71Lymphoma, Non-Hodgkin 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Leukemia, Myeloid, Acute 52Myelodysplastic Syndromes 50Neoplasms, Plasma Cell 48Hodgkin Disease 48Leukemia 42Leukemia, Lymphocytic, Chronic, B-Cell 40Lymphoma, Mantle-Cell 35Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Follicular 33Burkitt Lymphoma 24Lymphoma, B-Cell, Marginal Zone 22Lymphoma, Large-Cell, Immunoblastic 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 21Myeloproliferative Disorders 20Recurrence 19Hematologic Neoplasms 19Immunoglobulin Light-chain Amyloidosis 18Leukemia, Myelomonocytic, Chronic 16Neuroblastoma 15Leukemia, Myeloid, Chronic-Phase 15Leukemia, Myeloid, Accelerated Phase 15Graft vs Host Disease 15Dendritic Cell Sarcoma, Interdigitating 15Anemia, Refractory, with Excess of Blasts 14Waldenstrom Macroglobulinemia 12Primary Myelofibrosis 12

Interventions

pomalidomide 2daratumumab 2Dexamethasone 2ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1auricularum 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Gemcitabine 1Drug Combinations 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Plasmacytoma × Melphalan × Clear all
NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡